{
    "nctId": "NCT05935150",
    "briefTitle": "Omission of SLNB in CN0 Early Breast Cancer",
    "officialTitle": "Omission of Sentinel Lymph Node Biopsy (SLNB ) in Early Breast Cancer Patients with Clinically Assessed Negative Axillary Lymph Nodes (cN0): a Phase II, Prospective Clinical Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes, Sentinel Lymph Node",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 311,
    "primaryOutcomeMeasure": "invasive Disease-Free Survival (iDFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients aged 18-70 years;\n2. Pathologically confirmed invasive breast cancer (regardless of pathological type) with a tumor diameter \u2264 3 cm, and planning to undergo breast surgery;\n3. Negative axillary lymph nodes assessed by physical examination and imaging (2 or more of the following tests including ultrasound, breast MRI, breast PET-CT, breast PET-MRI, breast PET);\n4. All patients are required to undergo immunohistochemical staining for Estrogen Receptor (ER), Progesterone Receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67 proliferation index, and further fluorescence in situ hybridization (FISH) should be performed in HER2 2+ cases;\n5. Good compliance, normal comprehension and ability to receive treatment and follow-up as required;\n6. ECOG score 0-1;\n7. Patients volunteered for this study and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Bilateral/lactating/pregnant breast cancer;\n2. Previous history of malignant tumor or neoplasm;\n3. Clinical or imaging confirmation of distant metastasis;\n4. History of previous surgery on the affected axilla; or history of surgery affecting the function of the upper extremity;\n5. Prior history of radiotherapy to the breast or chest;\n6. Positive pathological margins after breast-conserving surgery or mastectomy;\n7. Severe coagulation disorder, or a serious systemic disease, or an uncontrollable infection;\n8. Aspartate aminortransferse (AST) and Alanine aminotransferase (ALT) \u2265 1.5 times the upper limit of normal, alkaline phosphatase \u2265 2.5 times the upper limit of normal, total bilirubin \u2265 1.5 times the upper limit of normal, serum creatinine \u2265 1.5 times the upper limit of normal; left ventricular injection fraction (LVEF) \\< 50% on cardiac ultrasound;\n9. Inability to complete the full course of follow-up adjuvant therapy as prescribed by the doctor for various reasons;\n10. No personal freedom and independent civil capacity;\n11. Presence of mental disorders, addictions, etc;\n12. Not eligible for enrollmentas as judged by the investigator.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}